Teladoc's stock pops as company partners with Microsoft on AI
Teladoc Health Inc. shares (TDOC) were moving more than 6% higher in Tuesday's premarket action after the telehealth company said it has expanded its partnership with Microsoft Corp. (MSFT) Teladoc "is furthering its collaboration with Microsoft" by "working together" on integrating Azure and Nuance artificial-intelligence tools into its platform. "We are focused on using AI to reassert and build the doctor-patient relationship at a time when technology frequently does the opposite," Vidya Raman-Tangella, Teladoc's chief medical officer, said in a release. Teladoc said in the release that the Nuance clinical-documentation tool will let doctors interact with their patients more without looking away to take notes on the visit.
-Emily Bary
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-18-23 0925ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing